Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fadc18369dac6778fe6217aed49ada7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6432 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
filingDate |
2019-07-23^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abf6c738d0ea1b72717dbace5593c3be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e652cb1cf998325aa0d2c5b27a137378 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1459936bda1a83588f833eb2a84e772 |
publicationDate |
2020-04-30^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020129597-A1 |
titleOfInvention |
MODULATION OF FACTOR Xa INHIBITOR-MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE |
abstract |
The present disclosure provides unit dose formulations and methods to reduce, stop or prevent bleeding in a patient undergoing anticoagulant therapy with a factor Xa inhibitor. The methods entail at least partial neutralization of the factor Xa inhibitors. The unit dose formulations and methods of the present disclosure can be effective even after actual bleeding has initiated. |
priorityDate |
2012-02-16^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |